France's Biosimilar Substitution May Lead to Erosion of Amgen

By: via Benzinga
The worst headwind for any pharmaceutic company is patent expiration. After the patent cliff comes an onslaught competition from generics and biosimilars that eats into sales. France just became the first European nation that allow pharmacists to substitute prescribed brand biological medicines for biosimilar medicine. The substitution can be made
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.